Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study

Willeke G. van der Plas-Krijgsman, Daniele Giardiello, Hein Putter, Ewout W. Steyerberg, Esther Bastiaannet, Anne M. Stiggelbout, Simon P. Mooijaart, Judith R. Kroep, Johanneke E.A. Portielje, Gerrit Jan Liefers*, Nienke A. de Glas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
3 Downloads (Pure)

Abstract

Background: Current prediction tools for breast cancer outcomes are not tailored to the older patient, in whom competing risk strongly influences treatment effects. We aimed to develop and validate a prediction tool for 5-year recurrence, overall mortality, and other-cause mortality for older patients (aged ≥65 years) with early invasive breast cancer and to estimate individualised expected benefits of adjuvant systemic treatment. Methods: We selected surgically treated patients with early invasive breast cancer (stage I–III) aged 65 years or older from the population-based FOCUS cohort in the Netherlands. We developed prediction models for 5-year recurrence, overall mortality, and other-cause mortality using cause-specific Cox proportional hazard models. External validation was performed in a Dutch Cancer registry cohort. Performance was evaluated with discrimination accuracy and calibration plots. Findings: We included 2744 female patients in the development cohort and 13631 female patients in the validation cohort. Median age was 74·8 years (range 65–98) in the development cohort and 76·0 years (70–101) in the validation cohort. 5-year follow-up was complete for more than 99% of all patients. We observed 343 and 1462 recurrences, and 831 and 3594 deaths, of which 586 and 2565 were without recurrence, in the development and validation cohort, respectively. The area under the receiver-operating-characteristic curve at 5 years in the external dataset was 0·76 (95% CI 0·75–0·76) for overall mortality, 0·76 (0·76–0·77) for recurrence, and 0·75 (0·74–0·75) for other-cause mortality. Interpretation: The PORTRET tool can accurately predict 5-year recurrence, overall mortality, and other-cause mortality in older patients with breast cancer. The tool can support shared decision making, especially since it provides individualised estimated benefits of adjuvant treatment. Funding: Dutch Cancer Foundation and ZonMw.

Original languageEnglish
Pages (from-to)e704-e711
JournalThe Lancet Healthy Longevity
Volume2
Issue number11
DOIs
Publication statusPublished - 1 Nov 2021

Bibliographical note

Funding Information:
This study was funded by the Dutch Cancer Foundation (KWF 2018–11387, Prediction of Outcome, Risk of Toxicity and quality of life in older patients TREaTed for breast cancer, the PORTRET study), and supported by ZonMw (grant number 843002623).

Funding Information:
This study was funded by the Dutch Cancer Foundation (KWF 2018?11387, Prediction of Outcome, Risk of Toxicity and quality of life in older patients TREaTed for breast cancer, the PORTRET study), and supported by ZonMw (grant number 843002623).

Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license

Fingerprint

Dive into the research topics of 'Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study'. Together they form a unique fingerprint.

Cite this